A detailed history of Raymond James Financial Inc transactions in Cassava Sciences Inc stock. As of the latest transaction made, Raymond James Financial Inc holds 62,250 shares of SAVA stock, worth $151,890. This represents 0.0% of its overall portfolio holdings.

Number of Shares
62,250
Holding current value
$151,890
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 06, 2025

BUY
$2.29 - $32.18 $142,552 - $2 Million
62,250 New
62,250 $146,000

Others Institutions Holding SAVA

About CASSAVA SCIENCES INC


  • Ticker SAVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,097,900
  • Market Cap $97.8M
  • Description
  • Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...
More about SAVA
Track This Portfolio

Track Raymond James Financial Inc Portfolio

Follow Raymond James Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Inc with notifications on news.